To include your compound in the COVID-19 Resource Center, submit it here.

Cutting cravings

Amygdala aims to treat addiction with ALDH2 inhibition

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently underserved by therapeutics, including alcohol abuse and cocaine and opioid addiction.

The compound inhibits aldehyde dehydrogenase 2 family mitochondrial (ALDH2), a target CV Therapeutics was working on when it was acquired by Gilead in 2009. ANS-6637 builds upon that work but was discovered by Gilead.

Read the full 792 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE